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Congenital long QT syndrome (LQTS) is a hereditary disorder that leads to sudden cardiac death secondary to fatal cardiac arrhythmias.
Although many genes for LQTS have been described, the etiology remains unknown in 30%–40% of cases. In the present study, a large
Chinese family (four generations, 49 individuals) with autosomal-dominant LQTS was clinically evaluated. Genome-wide linkage anal-
ysis was performed by using polymorphic microsatellite markers to map the genetic locus, and positional candidate genes were screened
by sequencing for mutations. The expression pattern and functional characteristics of the mutated protein were investigated by western
blotting and patch-clamp electrophysiology. The genetic locus of the LQTS-associated gene was mapped to chromosome 11q23.3-24.3.
A heterozygous mutation (Kir3.4-Gly387Arg) was identiﬁed in the G protein-coupled, inwardly rectifying potassium channel subunit
Kir3.4, encoded by the KCNJ5 gene. The Kir3.4-Gly387Arg mutation was present in all nine affected family members and absent in
528 ethnically matched controls. Western blotting of human cardiac tissue demonstrated signiﬁcant Kir3.4 expression levels in the
cardiac ventricles. Heterologous expression studies with Kir3.4-Gly387Arg revealed a loss-of-function electrophysiological phenotype
resulting from reduced plasma membrane expression. Our ﬁndings suggest a role for Kir3.4 in the etiology of LQTS.Introduction
Congenital long QT syndrome (LQTS; MIM 192500) is an
inherited cardiac disorder associated with a prolonged QT
interval on surface electrocardiogram (ECG), recurrent
syncope, and, in some cases, a predisposition to sudden
death from life-threatening cardiac arrhythmias, including
torsades de pointes and ventricular ﬁbrillation. The onset
of the deleterious arrhythmias is often associated with
emotional or physical stress.1 To date, mutations in 12
genes,2–13 including the genes encoding ion channels
and their associated proteins, have been identiﬁed in
hereditary LQTS. Mutations in these genes have been iden-
tiﬁed in approximately 60%–70% of the individuals
affected with LQTS.14 Despite considerable effort over the
past 15 years, the genes responsible for the remaining
30%–40% of LQTS cases remain to be determined.
LQTS originates from prolongation of cardiac cell
repolarization following depolarization of the cardiac
ventricles. Three potassium currents (IK1, IKs, and IKr) are
believed to be responsible for the majority of ventricular
repolarization.15 However, recent studies have demon-
strated that the G protein-coupled, inwardly rectifying
potassium channel current IKACh is masked by the consti-
tutively active potassium channel current IK1.
16,17 Thus,
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believed.17
IKACh is formed by a heteromultimeric or homomulti-
meric complex of Kir3.1 and 3.4 subunits.18–22 Kir3.4
(also called GIRK4), encoded by the KCNJ5 gene (MIM
600734), assembles into functional homomeric channels
with low channel activity, but Kir3.1 must coassemble
with Kir3.2, Kir3.3, or Kir3.4 to form a functional hetero-
meric channel.21,23–25 Interestingly, Kir3.4 knockout mice
have a modest resting tachycardia, an inability to regulate
heart rate in response to parasympathetic stimulation, and
a longer ventricular effective refractory period than wild-
type mice.26–28
In a large Chinese family with LQTS, we have identiﬁed
a mutation in the potassium channel Kir3.4 that results in
a defect in channel trafﬁcking and a reduction in the IKACh
current. The data suggest that the loss-of-function muta-
tion in Kir3.4 is associated with LQTS.Material and Methods
Identiﬁcation and Phenotypic Determination of LQTS
Patients
A large family with a history of LQTS was identiﬁed in the Liaon-
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standards established by local institutional review boards. Periph-
eral venous blood specimens were obtained and clinical data,
including medical records, ECG tracings, and echocardiogram
reports were collected. Control subjects consisted of 528 ethni-
cally matched normal healthy individuals. This investigation
was performed in accordance with the Helsinki Declaration and
was approved by the Research Ethics Committee of Tongji Univer-
sity School of Medicine, Shanghai, China. The diagnosis of LQTS
was made as described previously.29 The corrected QT interval
(QTc) was calculated with Bazett’s formula.30
Linkage Analyses
Genomic DNA was extracted with a Wizard Genomic DNA Puriﬁ-
cation Kit (Promega). Previously identiﬁed LQTS genes (KCNQ1
[MIM 607542], KCNH2 [MIM 152427], SCN5A [MIM 600163],
ANK2 [MIM 106410], KCNE1 [MIM 176261], KCNE2 [MIM
603796], KCNJ2 [MIM 600681], CACNA1C [MIM 114205], CAV3
[MIM 601253], SCN4B [MIM 608256], AKAP9 [MIM 604001],
and SNTA1 [MIM 601017]) were screened for mutations in the
proband (II-8) and another affected family member (II-4).2–13 A
genome-wide scan was performed with a set of 383 microsatellite
markers (ABI Prism Linkage Mapping Sets v2.5). Additional short
tandem repeat (STR) markers were used to ﬁne map the genetic
interval on chromosome 11. PCR products were pooled, and
product sizes were determined with a MegaBACE 500 DNA Anal-
ysis System (Amersham Biosciences). Two-point LOD scores were
calculated with the program SAGE 5.0 under an autosomal-domi-
nant genetic model with the disease allele frequency and pene-
trance of LQTS set at 0.003 and 95% respectively, evenly shared
allele frequency, and no sex difference.
Mutation Screening of the Positional Candidate Genes
The complete coding regions and intron/exon boundaries of the
positional candidate genes were ampliﬁed with HotStarTaq DNA
Polymerase (QIAGEN). Both strands of each PCR product were
sequenced with a DYEnamic ET Dye Terminator Kit (Amersham
Biosciences UK Limited) and the MegaBACE 500 DNA Analysis
System. For the mutated Kir3.4 protein, multiple protein
sequences from various species were aligned by using the software
program ClustalW.
Molecular Cloning and Transfection
Complementary DNAs encoding human Kir3.1 (GenBank acces-
sion number NM_002239), human Kir3.4 (GenBank accession
numberNM_000890), andhuman type 2muscarinic acetylcholine
(ACh) receptor (M2, GenBank accession number NM_001006630)
were kind gifts from D.E. Logothetis. The cDNAs were subcloned
into pcDNA3, and the hKir3.4-Gly387Arg mutation was intro-
duced via site-directed mutagenesis (Pfu Turbo DNA Polymerase,
Stratagene). All constructs were veriﬁed by DNA sequencing.
Human embryonic kidney cells (HEK293) were transiently co-
transfected with 0.6 mg pcDNA3-hM2, 0.6 mg pcDNA3-hKir3.1,
and 0.2 mg pcDNA3-eGFP (reporter gene), plus 0.6 mg wild-type
pcDNA3-hKir3.4, 0.6 mg pcDNA3-hKir3.4-Gly387Arg, or 0.3 mg
wild-typepcDNA3-hKir3.4 and0.3mgpcDNA3-hKir3.4-Gly387Arg.
Transfections were performedwith Lipofectamine and Plus reagent
(Invitrogen) according to the manufacturer’s instructions.
Electrophysiology
Patch-clamp experiments were performed 2 to 3 days after transfec-
tion. Whole-cell currents were measured in symmetrical RingerThe Amesolution at room temperature. The internal pipette solution con-
sisted of (in mM) KCl 141, EGTA 10, CaCl2 5.2, MgCl2 1.42, and
HEPES 10 (pH 7.4 with KOH); the external solution consisted of
(in mM) KCl 140, CaCl2 2.6, MgCl2 1.2, and HEPES 5 (pH 7.4 with
KOH). 10 mM ACh was freshly prepared prior to each experiment
and added to the external solution. Cells were constantly perfused
with 10 mM Ach. Measurements were made with PULSE software
(HEKA Elektronik) and an EPC-9 ampliﬁer sampling at 2.5 kHz
and ﬁltering at 1.25 kHz (HEKA Elektronik). Borosilicate glass
pipettes were pulled on a DPZ-Universal puller (Zeit Instrumente,
Munich). The pipettes had a resistance of 1.5–2.5 MU when ﬁlled
with intracellular solution. The series resistance recorded in the
whole-cell conﬁguration was 2–4MU and was compensated (80%).
The seal resistance in all experiments was greater than 1.0 GU.Protein Extraction and Western Blotting
Right atrium lateral wall (RA) and left ventricular endocardial free
wall (LV) specimens (n ¼ 4) were obtained from patients under-
going valve replacement surgery at Rigshospitalet, University of
Copenhagen, Denmark. Total membrane proteins were puriﬁed
via a method modiﬁed from Han et al.31 Because surface
membrane-associated proteins were primarily harvested by this
extraction method, we ascertained that neither cytochrome c
nor b-tubulin or actin were suitable as loading controls. Great
care was taken to load exactly the same amount of total membrane
protein onto gels, and western blotting experiments were repeated
several times. The cell surface biotinylation procedure was per-
formed as previously described.32
Total lysate (20 mg per lane human tissue extract) and HEK293
biotinylated and unbound fractions (15 mg per sample in the bio-
tinylation procedure) were separated on 4%–15% SDS-PAGE via
a minigel system (Bio-Rad). Proteins were transferred onto Hy-
bond-P polyvinylidene diﬂuoride transfer membranes (Amersham
Biosciences, 0.45 mm), and membranes were blocked in 5% nonfat
milk in TBST (0.1% Tween 20 in Tris-buffered saline solution) for 2
hr at room temperature and then incubated with primary anti-
body against Kir3.1 (1:1,000; Alomone Labs), Kir3.4 (1:1,000; Alo-
mone Labs), calnexin (1:2,000; Nordic Biosite), or Naþ/Kþ-ATPase
a1 (1:500; Santa Cruz Biotechnology) overnight. Proteins were de-
tected with HRP-conjugated donkey anti-mouse and anti-rabbit
secondary antibodies (1:10,000; Jackson ImmunoResearch Labora-
tories). Enhanced chemiluminescence (ECL) incubation was per-
formed via a standard procedure (SuperSignal West Pico Chemilu-
minescent detection system, Pierce), and immunoblots were
exposed on Hyperﬁlm ECL (Amersham Biosciences). Band density
was quantiﬁed with Quantity One software as a Gaussian trace
quantity on the exposed ﬁlms; quantiﬁed band densities were pro-
cessed equally.Statistical Analyses
All data are presented as mean5 standard error of the mean. For
statistical analyses, paired and unpaired t tests and two-way anal-
ysis of variance combined with a Bonferroni post hoc test were
used. p < 0.05 was considered statistically signiﬁcant.Results
Clinical Characteristics
The proband is a 64-year-old woman (II-8, Figure 1)
referred for a cardiology consultation following recurrentrican Journal of Human Genetics 86, 872–880, June 11, 2010 873
Figure 1. Pedigree and Mapping Analysis of a Family with Congenital Long QT Syndrome
Black squares and circles represent male and female affected subjects, respectively; white squares and circles represent unaffected
subjects; gray symbols represent subjects with clinical status undetermined. Slashes through symbols indicate deceased individuals;
the arrow denotes the proband. A vertical bar beneath a family member indicates the presence of the chromosomal segment as deter-
mined by genetic evaluation. Kir3.4 is located at 11q24.3, and themarkers tested in this region of chromosome 11 are listed to the left of
the pedigree, with each individual’s allele (represented by numbers) for each marker shown next to the chromosome bar. The chromo-
somal segment originating from the mutation-carrying chromosome of the affected individual in the ﬁrst generation (I-2) is represented
by the black bar.syncopal episodes that began when she was 22 years old.
Since that time, she had experienced 32 syncopal episodes,
the majority of which were preceded by emotional or
physical stress. She therefore underwent a comprehensive
clinical evaluation including echocardiography and ECG
recordings. The echocardiogram did not uncover any struc-
tural or functional cardiac abnormalities. However, the
ECG revealed a markedly prolonged QT interval (QTc ¼
520 ms). A representative 12-lead ECG is shown in
Figure 2A. She was treated with metoprolol 50–75 mg PO
twice daily. Subsequent evaluation of 49 family members
identiﬁed nine patients with LQTS characterized by similar
clinical features. The participant pedigree is shown in
Figure 1, and a summary of clinical characteristics of the
affected members is listed in Table 1. Transmission of
LQTS in this family occurred in an autosomal-dominant
pattern. Interestingly, the proband also developed persis-
tent atrial ﬁbrillation (AF;MIM608583) (Figure 2B). Perma-
nent AF was also observed in affected subjects I-2 and II-4;
subject I-2’s elder sister was also diagnosed with LQTS and
permanent AF (data not shown). Subject II-13, from
whom blood samples were not obtained, suffered from
a series of seizures and syncopal episodes and died suddenly
7 days after birth.874 The American Journal of Human Genetics 86, 872–880, June 11,Chromosomal Location
Sequencing of 12 known LQTS genes did not reveal any
mutational change in two affected family members,
excluding the possibility of their causative effect. Thus,
we assumed that the observed LQTS syndrome in the
current pedigree could be caused by an unknown gene
that was expected to be identiﬁed by performing a
genome-wide linkage analyses. Initial evidence of linkage
was obtained with marker D11S4151 on chromosome
11q23 with a two-point LOD score of 1.74 (at recombina-
tion fraction [q] ¼ 0.00). Fine mapping of the region
resulted in positive two-point LOD scores for sequential
markers from D11S4110 to D11S4123 with a peak
LOD score of 5.12 (at q ¼ 0.00) at D11S4123 on chromo-
some 11q24.3 (Table 2). Haplotype analyses indicated
a shared region (11q23.3-24.3) among affected family
members ﬂanked by markers D11S4151 and D11S4123,
corresponding to a genetic distance of approximately
4.78 cM.
Identiﬁcation of a Mutation in Kir3.4
A bioinformatic analysis revealed 15 deﬁned genes in the
above chromosomal region. Among these genes, two ion
channel genes were considered strong candidate genes2010
Figure 2. The Kir3.4-Gly387Arg Muta-
tion Is Associated with Congenital Long
QT Syndrome
(A and B) Representative 12-lead surface
electrocardiograms from the proband,
demonstrating a prolonged QT interval
(A) and atrial ﬁbrillation (B).
(C) Sequencing of genomic DNA from the
proband revealed a heterozygous muta-
tion in Kir3.4. The G-to-C substitution
results in the introduction of an arginine
(R) instead of the normal glycine (G) at
codon 387 (Gly387Arg).
(D) Alignment of Kir3.4 protein sequences
across species demonstrating that Gly387
is conserved throughout evolution.for LQTS: KCNJ1 (MIM 600359), encoding Kir1.1, and
KCNJ5, encoding Kir3.4. Upon sequencing of each candi-
date, a heterozygous mutation was identiﬁed in Kir3.4. A
cytosine-to-guanine substitution at nucleotide 1473
(c.1473C>G) was identiﬁed in KCNJ5 that resulted in
a change in the Kir3.4 amino acid residue 387 from glycine
to arginine (Gly387Arg) (Figure 2C). A cross-species align-
ment of the Kir3.4 protein sequence demonstrated that
Gly387Arg is highly conserved across species (Figure 2D).
The Gly387Arg mutation was present in all nine affected
family members and absent in 528 ethnically matched
controls. Interestingly, LQTS is incompletely penetrant in
subject III-5 and III-22, pointing toward the need for
long-term monitoring of asymptomatic subjects carrying
the Gly387 allele in order to conﬁrm its clinical signiﬁ-
cance.The American Journal of HumanElectrophysiological Analysis of
Mutated Kir3.4
The functional effects of the Kir3.4-
Gly387Arg mutation were examined
by patch-clamp analyses on HEK293
cells cotransfected with Kir3.1 plus
Kir3.4, Kir3.4 and Kir3.4-Gly387Arg,
or Kir3.4-Gly387Arg. Coexpression
of Kir3.1/Kir3.4-Gly387Arg or Kir3.1/
Kir3.4/Kir3.4-Gly387Arg in HEK293
cells resulted in a drastic reduction of
inward currents compared to wild-
type Kir3.1/Kir3.4 (Figure 3). The fact
that heterozygous expression of wild-
type and mutant Kir3.4 gives low
current amplitude indicates that
Kir3.4-Gly387Arg has a dominant-
negative effect.
Kir3.1 and Kir3.4 Protein
Trafﬁcking
Because the Gly387Arg mutation
resides in a region of Kir3.4 previ-
ously described to be involved inthe surface targeting of the heteromeric Kir3.1/Kir3.4
complex,33 we decided to examine whether a reduced
surface expression of the two subunits could explain
the Kir3.4-Gly387Arg-induced current reduction. To this
end, cell surface and intracellular Kir3.4 and Kir3.1 were
analyzed via western blotting of cells cotransfected
with Kir3.4-Gly387Arg/Kir3.1 or wild-type Kir3.4/Kir3.1
(Figure 4). In Kir3.4-Gly387Arg/Kir3.1-cotransfected cells,
the plasma membrane and intracellular expression levels
of Kir3.4 and Kir3.1 were markedly reduced compared
to that of control (wild-type Kir3.4/Kir3.1) (Figure 4).
Cotransfection of wild-type Kir3.4 together with Kir3.4-
Gly387Arg and Kir3.1 completely recovered the intracel-
lular Kir3.4 and Kir3.1 levels but failed to recover the
expression of both Kir3.4 and Kir3.1 on the cell surface
(Figure 4).Genetics 86, 872–880, June 11, 2010 875
Table 1. Clinical Characteristics of the Pedigree Members with Kir3.4-Gly387Arg or Sudden Death
Subject Information Symptom Electrocardiogram Echocardiogram
Identity Gender Age (Years) Recurrent Syncope Recurrent Palpitation QTc (ms) Other Findings LVEDD (mm) LVEF (%)
I-2 F 72a þ þ NA Permanent AF NA NA
II-2 F 67a þ þ 490 AT, TdP NA NA
II-4 F 66 þ þ 560 Permanent AF 60 50
II-8 F 64 þ þ 520 Persistent AF 50 54
II-9 M 60 þ þ 450 AT 40 57
II-12 F 48 þ þ 470  49 64
II-13 M 7 daysa þ NA NA NA NA NA
III-3 M 48 þ þ 450  49 71
III-5 M 40  þ 430  52 64
III-15 F 38 þ þ 470  40 61
III-22 F 35  þ 460  39 65
IV-1 F 13 þ þ 460  36 72
The following abbreviations are used: QTc, QT interval corrected for heart rate; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection frac-
tion; þ, present; , absent; NA, not available or not applicable; AF, atrial fibrillation; AT, atrial tachycardia; TdP, torsades de pointes.
a Age at death.Human Cardiac Kir3.1 and Kir3.4 Protein Expression
Atrial and endocardial left ventricular tissue samples were
obtained from four patients undergoing cardiac valve
surgery. Protein was extracted from these samples, and
western blotting was performed (Figure 5). Both Kir3.1
and Kir3.4 were demonstrated to be expressed in the atria
as well as the ventricles.Table 2. Two-Point LOD Scores
Marker
Recombination Fraction
0.00 0.01 0.05 0.10 0.20 0.30 0.40
D11S933 1.08 0.91 0.06 0.31 0.48 0.39 0.20
D11S990 () 0.57 1.07 1.14 0.94 0.58 0.20
D11S4151 1.74 1.70 1.56 1.37 0.98 0.56 0.19
D11S4110 2.05 2.01 1.84 1.63 1.18 0.71 0.25
D11S1351 3.74 3.67 3.38 3.02 2.24 1.40 0.55
D11S912 4.34 4.26 3.94 3.52 2.64 1.69 0.67
D11S4123 5.12 5.03 4.67 4.20 3.18 2.04 0.81
D11S2367 () 2.95 0.44 0.39 0.78 0.60 0.23
D11S4126 0.05 0.04 0.00 0.02 0.03 0.02 0.01Discussion
We have identiﬁed KCNJ5, encoding Kir3.4, as a causative
gene in LQTS. In a large Chinese family with LQTS, we de-
tected a mutation, Gly387Arg, in a highly conserved
residue in Kir3.4. The Kir3.4-Gly387Arg mutation resulted
in a loss of IKACh channel function by disrupting
membrane targeting and stability of Kir3.4.
In the heart, the functional IKACh channels are formed
largely by heteromeric Kir3.4 and Kir3.1 subunits.26 In
this study, we determined that, when cotransfected in
HEK293 cells, the expression of Kir3.4-Gly387Arg led to
reduced levels of Kir3.4 and Kir3.1 in both the plasma
membrane and cytoplasmic fractions, indicating that this
mutation in Kir3.4 leads to defects in Kir3.4 and Kir3.1
membrane targeting and stability. Interestingly, the coex-
pression of wild-type Kir3.4, Kir3.4-Gly387Arg, and
Kir3.1, a situation mimicking the in vivo heterozygous
expression of Kir3.4 in patients with LQTS as described
in this study, rescued the cytoplasmic expression levels of
Kir3.4 and Kir3.1 but failed to rescue defects in membrane
targeting of these proteins. This suggests that the Kir3.4-
Gly387Arg mutation interferes with the formation of func-
tional channels containing Kir3.4. As a consequence,876 The American Journal of Human Genetics 86, 872–880, June 11,Gly387Arg mutant channels exhibited a near complete
loss of channel activity and failed to respond to ACh stim-
ulation.
IKACh is predominantly expressed in the sinoatrial node,
atria, and atrioventricular node.34 Biochemical and genetic
studies have demonstrated that IKACh plays an important
role in both parasympathetic slowing of the heart rate
and repolarization of atrial action potentials.34 The mech-
anism of function of Kir3.4 in the context of Kir3.1 is also
well established in the atria. Parasympathetic release of
ACh leads to activation of the muscarinic M2 receptor,
which in turn activates Kir3.1/Kir3.4 channels via G
protein bg subunits.33 However, the role of Kir3.1/Kir3.4
channels in ventricular function is less clear. IKACh has
been recorded in the ventricular myocytes of multiple2010
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Figure 3. Electrophysiological Analyses of Kir3.4-Gly387Arg
Whole-cell patch clamping of HEK293 cells transiently transfected with hKir3.1/hKir3.4, hKir3.1/hKir3.4/hKir3.4-Gly387Arg, or
hKir3.1/hKir3.4-Gly387Arg. Note: G387R in this ﬁgure is equivalent to Gly387Arg.
(A) Representative traces. Current was recorded in response to a 1000ms voltage ramp from100 toþ50mV from a holding potential of
0 mV (inset at top). Symmetrical potassium ion solutions with 10 mM acetylcholine (ACh) were used.
(B) Normalized average5 standard error of the mean (SEM) current density values measured at 100 mV (current was elicited by the
ramp protocol described above). hKir3.1/hKir3.4: 40.96 5 6.75 pA/pF; hKir3.1/hKir3.4/hKir3.4-Gly387Arg: 15.69 5 0.95 pA/pF;
hKir3.1/hKir3.4-Gly387Arg: 9.92 5 1.32 pA/pF; mock-transfected cells: 6.83 5 0.86 pA/pF. *p < 0.05, ***p < 0.001 versus
hKir3.1/hKir3.4.
(C) Representative traces. Current was recorded during 1000 ms voltage-clamp pulses from 120 to þ60 mV in 20 mV steps from
a holding potential of 0 mV (inset at lower right).
(D) Current-voltage relationships of hKir3.1/hKir3.4, hKir3.1/hKir3.4/hKir3.4-Gly387Arg, and hKir3.1/hKir3.4-Gly387Arg with that of
mock-transfected HEK cells as control. To measure current-voltage relationships, current was elicited by the step protocol described
above, and current amplitudes were measured at the end of each voltage step. Kir3.1/3.4 was signiﬁcantly different from Kir3.1/
Kir3.4/Kir3.4-Gly387Arg or Kir3.1/Kir3.4-Gly387Arg by two-way analysis of variance (*p < 0.05, **p < 0.01, ***p < 0.001 versus
hKir3.1/hKir3.4). Kir3.1/Kir3.4/Kir3.4-Gly387Arg was not signiﬁcantly different from Kir3.1/Kir3.4-Gly387Arg. At 60 mV, the average
current was19.135 2.96 pA/pF for Kir3.1/Kir3.4,8.395 1.14 pA/pF for Kir3.1/Kir3.4/Kir3.4-Gly387Arg, and6.225 0.84 pA/pF for
Kir3.1/Kir3.4-Gly387Arg.species including human,35 ferret,36 and dog.37 Other
studies have shown that adenosine or sphingosine-1-phos-
phate receptor stimulation may activate an IKACh-like
current in ferret and mouse ventricular myocytes,38,39 sug-
gesting that the activation of IKACh in ventricles may be
distinct from the predominantly muscarinic activation in
atria. The relatively uncharacterized role of Kir3.1/Kir3.4
channels in the ventricles could also be due to their resem-
blance to IK1.
16,17
Genetic studies have demonstrated that Kir3.1 or Kir3.4
knockout mice exhibit a modest resting tachycardia and
inability to regulate heart rate changes secondary to para-
sympathetic stimulation.26–28 The loss-of-function
phenotype in mice is strikingly different from that seen
in the human patients described in this study. The reasons
behind this apparent discrepancy remain unclear, but
several possible mechanisms can be hypothesized. First,The Amethe differences observed between mice and humans may
simply reﬂect differences between species, inasmuch as
other Kir3 family members in mice may compensate for
the loss of Kir3.4 in the ventricle. Second, the phenotype
of the Gly387Arg mutation observed in humans may be
attributable to a loss of function of both Kir3.4 and
Kir3.1, because the mutant protein appears to affect tar-
geting and stability of both Kir3.4 and Kir3.1. Interest-
ingly, normal Kir3.1 membrane location is impaired in
the myocytes of Kir3.4 knockout mice, which supports
our ﬁnding of a Kir3.4-Gly387Arg mutation-induced
Kir3.1 membrane targeting defect.28 Nevertheless, our
analyses have revealed a physiological and pathophysio-
logical function for the Kir3.4 protein in human ventric-
ular myocytes.
Although AF is signiﬁcantly more common in patients
with LQTS compared to the general population,40 little isrican Journal of Human Genetics 86, 872–880, June 11, 2010 877
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Figure 4. Cell Surface Expression of Kir3.4-Gly387Arg and Kir3.1
Western blotting of HEK293 cells transiently cotransfected with hKir3.1 and hKir3.4 or hKir3.4-Gly387Arg. Note: G387R in this ﬁgure is
equivalent to Gly387Arg.
(A) Representative exposures of biotinylated proteins and unbound protein fractions with the indicated antibodies (AB). For mock-trans-
fected HEK293 cells, whole-cell lysate was loaded. Naþ/Kþ-ATPase a1 served as a loading control to make sure that equal amounts of cell
lysates were loaded onto the gel. Calnexin, which is an endoplasmic-reticulum-resident protein, served as control for selective biotiny-
lation of plasma membrane proteins.
(B) Average5 SEM values from quantiﬁcation of six independent experiments. *p < 0.05, **p < 0.001.known about the molecular mechanisms underlying
LQTS-coexistent arrhythmias. In the present study, three
of the affected individuals presented with permanent or
persistent AF, and an additional two affected individuals
experienced atrial tachycardia (Table 1), suggesting that
Kir3.4-Gly387Arg may affect both the atria and the ventri-
cles. In fact, upregulation of IKACh has been reported in AF
and has long been speculated to play a role in the inci-
dence and persistence of AF.41 It has also become increas-
ingly clear that heterogeneity in repolarization may
promote arrhythmias such as AF.42,43 Thus, we hypothe-
size that the Gly387Arg mutation in Kir3.4 may create
sufﬁcient atrial repolarization heterogeneity to contribute
to AF or atrial tachycardia in affected patients.
In conclusion, a mutation in Kir3.4 exerts dominant-
negative effects on Kir3.1/Kir3.4 channel complexes, link-
ing it to congenital LQTS. This suggests a potential role for
these channels in ventricular repolarization.Supplemental Data
Supplemental Data include one table and can be found with this
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Figure 5. Human Atrial and Ventricular Expression of Kir3.1 and
Kir3.4
(A) Western blotting of proteins extracted from tissue from the left
ventricular endocardial free wall (LV) and the lateral wall of the
right atrium (RA) from four patients (e.g., patient 1: LV1 and RA1).
(B and C) Quantiﬁcation of expression levels of Kir3.1 (B) and
Kir3.4 (C) in the atria and ventricles. Average 5 SEM arbitrary
quantiﬁcation values for atrial versus ventricular expression were
as follows: Kir3.1, 2375 54 versus 625 7; Kir3.4, 1825 5 versus
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